Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Shreyaskumar PatelMargaret von MehrenDamon R ReedPamela KaiserJohn CharlsonChristopher W RyanDaniel RushingMichael LivingstonArun SinghRahul SethCharles ForscherGina D'AmatoSant P ChawlaSharon McCarthyGeorge WangTrilok ParekhRoland KnoblauchMartee L HensleyRobert G MakiGeorge D DemetriPublished in: Cancer (2019)
The final OS results demonstrated comparable survival between LPS/LMS patients receiving trabectedin or dacarbazine, which is consistent with the interim analysis results. Both LPS and LMS demonstrated improved disease control with trabectedin.